Search a ticker

Categories
Featured Health Care Stocks Investing Stock Market Today

Best Health Care Stocks To Buy Before September 2021? 4 For Your Watchlist

With coronavirus cases on the rise again, should you be keeping tabs on health care stocks?

best health care stocks to buy

Should Investors Be Focusing On These Health Care Stocks? 

Health care stocks have been back in focus recently in the stock market. Unsurprisingly, this came with the rising concern of the Delta variant of coronavirus. Even health officials in the U.S. are preparing to distribute booster shots of the COVID-19 vaccine. As it stands, it has been established that immunity starts to wane after the initial two doses with the dominance of the Delta variant. Dominant vaccine companies such as Johnson & Johnson (NYSE: JNJ) and Moderna Inc (NASDAQ: MRNA) are wasting no time in researching the need for booster shots.

JNJ claims that it is currently engaging with the FDA, CDC, and other health authorities and will share new data shortly regarding its booster dose. Meanwhile, Moderna remains confident in its vaccine efficacy as it claims that its vaccine remained 93% effective in the first six months after the second dose. Overall, governments around the world are on high alert to prevent the pandemic from getting worse. Well, all this bodes well for health care companies as it only further highlights the importance of their products and services. So, would a list of the top health care stocks in the stock market today interest you?

Top Health Care Stocks To Watch Today 

Pfizer Inc 

By now, everyone would be aware of Pfizer for its pivotal role in developing the coronavirus vaccine. That said, some may not know that it also offers biopharmaceutical products worldwide in various therapeutic areas that include cardiovascular, metabolic, pneumococcal diseases, and many others. PFE stock has been up by over 30% since the start of the year.

On Monday, the company and BioNTech SE (NASDAQ: BNTX) announced that they have submitted Phase 1 data to the U.S. FDA to support evaluating a booster dose of the companies’ COVID-19 vaccine. Also, these data will be submitted to other regulatory authorities in the coming weeks. The data suggests that the third dose of vaccine elicits antibody levels that significantly exceed those with just two doses. Vaccination remains our most effective means of combating coronavirus infection and Pfizer is not wasting any time in improving its vaccination regimen.  

Furthermore, the company has also gained approval from the FDA for its TICOVAC™ (tick-borne encephalitis(TBE) vaccine). This is for active immunization to prevent TBE in individuals 1 year of age and older. As of now, TOCIVAC will be the only U.S. FDA-approved vaccine to protect against the TBE virus when visiting or living in TBE endemic areas. With all these in mind, would you consider adding PFE stock to your watchlist? 

Source: TD Ameritrade TOS

Read More

Eli Lilly And Co 

Following that, we have Eli Lilly and Co. In detail, it is a company that specializes in human pharmaceutical products. Founded more than a century ago, the company is committed to creating high-quality medicines that meet real needs. Among the company’s most notable achievements include being the first company to mass-produce the polio vaccine and insulin. 

Just today, the U.S. FDA has approved the company’s Jardiance (empagliflozin) 10mg. The drug is used to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with a reduced ejection fraction (HFrEF). This new treatment option is critical as approximately half of all people with heart failure will die within five years of diagnosis. So, this marks yet another important milestone for the company in its effort to transform care for adults with heart failure.

Not only that, but the company also gained FDA approval for its rapid-acting insulin, Lyumjev (insulin lispro-aabc injection) 100 units/mL for use in insulin pumps. This is indicated to improve glycemic control in adults with type 1 and type 2 diabetes. The Lyumjev label’s expansion to include use in an insulin pump now provides a new choice for people with diabetes. All in all, it has been an exciting week for the company with its string of FDA approvals. Thus, would LLY stock be on the top of your watchlist? 

Source: TD Ameritrade TOS

[Read More] Best Lithium Battery Stocks To Buy Now? 4 To Know

GlaxoSmithKline plc

GlaxoSmithKline (GSK) is a multinational pharmaceutical company with a wide portfolio of treatments and drugs. It is a global healthcare company that has developed many life-changing drugs in the last 20 years. For instance, the company was the first to develop the malaria vaccine. It also has legacy products like Amoxicillin, an antibiotic used to treat many bacterial infections.  

On Tuesday, GSK announced the U.S. FDA has approved a new indication for JEMPERLI (dostarlimab-gxly). This is a programmed cell death receptor-1 (PD-1) blocking antibody for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors. The drug received accelerated approval based on tumor response rate and durability of response. So, this is good news for patients with tumors expressing the dMMR biomarker as there is a significant need for new and effective treatments 

On top of that, investors should also be aware that the company along with Vir Biotechnology, Inc (NASDAQ: VIR) has signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab. The drug is used for the treatment of patients with COVID-19 who do not require oxygen supplementation and are at risk of progressing to severe COVID-19. Considering these developments, would you invest in GSK stock? 

Source: TD Ameritrade TOS

[Read More] Top Stocks To Buy Now? 5 Dividend Stocks To Watch

Regeneron Pharmaceuticals Inc 

To sum up this list, we have a biopharmaceutical company that specializes in the treatment of serious medical conditions, Regeneron. It commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and has product candidates in other areas such as rheumatoid arthritis, asthma, and many other infectious diseases. Since the start of the year, REGN stock has risen by over 30%.   

With its strong fundamentals throughout the years, Regeneron continues to post healthy financial results. For its second quarter, the company posted revenues of $5.14 billion, an increase of a whopping 163% year-over-year. Furthermore, its net income skyrocketed to $3.1 billion, representing an increase of 245% year-over-year. The strong quarter is largely due to the company delivering its entire order of COVID-19 antibody cocktails to the U.S. government.  

Regeneron also received a boost from its Phase 3 trial of Libtayo (cemiplimab-rwlc) combined with chemotherapy. Significant improvement in overall survivability in patients with first-line advanced non-small-cell lung cancer has allowed the trial to stop early. It appears that the combination increases the median overall survival to 22 months compared to 13 months with chemotherapy alone. So, the decision to stop the trial early was based on a recommendation by the Independent Data Monitoring Committee. Overall, this is a step in the right direction and investors could be expecting more positive news ahead. Given all these, would REGN stock have more room to run?

Source: TD Ameritrade TOS

By Adam Lawrence

Adam Lawrence is a serial entrepreneur and financial writer for StockMarket.com. He calls Miami, Florida his home but has a love for travel. He started his first digital marketing and website design business, in 2006 at the age of 23. He has worked with and consulted for hundreds of publicly traded companies. His vast knowledge of the public markets has allowed him to gain real-world experience in corporate communications. No matter what is going on in the stock market today, Adam is at the front of the line to track new trends and present them to readers.

As an active contributor to other financial sites like GuruFocus and Benzinga, Adam has gained prominence for reporting on several topics. These include biotech stocks, technology stocks, gold stocks, as well as marijuana stocks. These active stock market sectors have presented investors with some of the biggest opportunities in the stock market today. Adam's goal is to present readers with easily digestible content that is both informative and actionable.

Adam's years of experience in digital marketing have helped give him an edge above other financial writers. His ability to pick up on stock market trends before they hit Main Street is one of the things that has afforded him the opportunity to interact with and engage public companies. Reporting on current events is one thing but being able to dissect them and translate them for readers is of the utmost importance. In doing so, Adam has set a personal standard to deliver timely information that dives deeper than simple headlines and goes into the fine details of what's driving stock market trends. He also stays on top of the most current social media trends among top influencers.

With the emerging landscape surrounding new media, Adam takes an active approach to learn what drives interest in different social media and finds ways to tap into whatever is trending at that time then apply it to his approach to the stock market. In his free time, he enjoys being with his family and working on his house. He's also an avid car enthusiast.

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments